Merck & Co signs multi-billion cancer drug development deal ...

Merck & Co has signed a multi-billion cancer drug development deal, which will see it investing $1 billion in partner Seattle Genetics.

UK government invests £32m in health tech projects

The UK government is to invest £32 million ($41.5 million) in six health technology projects aiming to transform care for debilitating diseases such as cancer and osteoarthritis.

Blueprint and Roche take on Lilly as FDA approves RET-target...

Cancer drugs firm Blueprint Medicines has gained a second US approval, with its Gavreto (pralsetinib) daily pill that targets non-small cell lung cancer with RET fusion mutations.<

In the precision medicine era, the line between products and...

Protein Misfolding Drug Discovery Summit

Discover & Translate Disease-Modifying Therapeutics

Highlight Therapeutics trials second-line melanoma combo aft...

Cancer immunotherapy has set new standards in care, with some impressive responses in those patients lucky enough to respond.